Posters

Feasibility, safety and efficacy of combined phacoemulsification and limited pars plana vitrectomy for management of acute angle closure due to phacomorphic glaucoma

Poster Details

First Author: S.Reddy INDIA

Co Author(s):    S. Brar   S. Ganesh                 

Abstract Details

Purpose:

To evaluate the feasibility, safety and efficacy of combined phacoemulsification and limited pars plana vitrectomy in acute angle closure glaucoma

Setting:

Nethradhama superspeciality eye hospital, Bangalore

Methods:

Retrospective analysis of 10 eyes of 10 patients who underwent phacoemulsification and limited pars plana vitrectomy for acute angle closure due to phacomorphic glaucoma presenting in the past 1 year was performed. A 23/25-G valve trocar cannula was used to perform limited vitrectomy, just enough to cause mild softening of the globe following which the phacoemulsification could be performed safely, without any intraoperative complications such as, radialisation of rhexis, PCR, ZD or vitreous loss.

Results:

The mean age of the patients was 62+/-0.45 years, the mean preoperative IOP was 68+/-2 mm Hg, presenting visual acuity was either HM or PL+. The mean ACD measured with IOL master 700 was 2.02+/-0.15mm. On post operatively day 1, all patients had significant reduction in IOP and improvement in visual acuity. The mean IOP was 12+/-2.4mmHg and the mean visual acuity (log MAR) was 0.2 +/- 0.13. The mean postoperative ACD increased to 3.24+/-0.36mm. All patients had IOP values within normal limits post-surgery, without the need of anti-glaucoma medications. The disc changes remained stable throughout the mean follow up of 6 months.

Conclusions:

Combined phacoemulsification and limited pars plana vitrectomy was safe and effective for management of acute angle closure due to phacomorphic glaucoma. The potential advantages of this technique are debulking of vitreous leading to a controlled anterior chamber deepening, facilitating safe phacoemulsification and eliminating the need of anti- glaucoma medications postoperatively

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a competing company